Table 1. Anti-B-CLL reactivity of... | American Society of Hematology

Table 1.

Anti-B-CLL reactivity of allogeneic anti—third-party CTLs

	B-CLL			B-CLL + anti—third-party CTL
Patient no.	Mice per group, n	% CD19/20⁺CD5⁺	Mice per group, n	% CD19/20⁺CD5⁺	% B-CLL eradication^*
1	3	3.6	3	0.2	94.4†
2	4	5.7	5	2.9	49.1†
3	2	0.22	2	0.045	79.5 (NS)
4	2	54.9	2	0.7	98.7 (NS)
5	5	18.6	5	3.1	83.3‡
6	3	56.7	5	4.1	92.7§

	B-CLL			B-CLL + anti—third-party CTL
Patient no.	Mice per group, n	% CD19/20⁺CD5⁺	Mice per group, n	% CD19/20⁺CD5⁺	% B-CLL eradication^*
1	3	3.6	3	0.2	94.4†
2	4	5.7	5	2.9	49.1†
3	2	0.22	2	0.045	79.5 (NS)
4	2	54.9	2	0.7	98.7 (NS)
5	5	18.6	5	3.1	83.3‡
6	3	56.7	5	4.1	92.7§

NS indicates not significant.

This value was calculated as follows: [% untreated − % treated/untreated] × 100.

Pf < .05.

Pf < .0005.

Pf < 5 × 10⁻⁵.